NICE recommends Tobi Podhaler (Novartis) for treatment of Cystic Fibrosis

NICE has recommended the use of Tobi Podhaler (tobramycin inhalation powder) from Novartis for the treatment of pseudomonas lung infection in Cystic Fibrosis patients aged six years and above. Tobi Podhaler may only be used in cases where treatment with the nebulised form of the drug is considered appropriate, i.e. when patients cannot have or do not respond to treatment with nebulised colistimethate. The NICE recommendation is also contingent upon the continued availability of a confidential patient access scheme agreed with Novartis, under which the Tobi Podhaler is provided at a discounted price, helping to boost its cost effectiveness.